Global Graft Versus Host Disease (GvHD) Treatment Market Report 2024

The graft versus host disease (GVHD) market size has grown strongly in recent years. It will grow from $2.65 billion in 2023 to $2.85 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth observed during the historic period can be attributed to several factors, including an increase in the number of allogeneic transplantations, a growing incidence of acute GVHD, an increasing rate of hematopoietic stem cell treatments, rising demand for bone marrow transplants, the escalating prevalence of GVHD worldwide, a rise in chronic GVHD cases, advancements in technology, and an increase in the patient population.

The graft versus host disease (GVHD) market size is expected to see strong growth in the next few years. It will grow to $3.82 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The anticipated growth in the forecast period can be attributed to several factors, including an increase in the number of allogeneic transplantations, a growing incidence of acute GVHD, an increasing rate of hematopoietic stem cell treatment, rising demand for bone marrow transplants, the rising prevalence of GVHD worldwide, an increase in chronic GVHD cases, advancements in technology, and a rise in the patient population. Major trends expected in the forecast period include partnerships, investments, product approvals, and customizations.

The anticipated rise in hematological disorders is expected to drive the growth of the graft versus host disease (GVHD) treatment market in the foreseeable future. Hematological disorders, which encompass various conditions affecting the blood and its components, are becoming more prevalent due to factors such as unhealthy lifestyle habits, genetic predisposition, and exposure to environmental toxins such as radiation, chemicals, and pollutants. Treatment strategies developed for managing GVHD can have broader implications for patients with hematological disorders, presenting new opportunities for immune modulation and improved disease management. For example, according to the Leukemia & Lymphoma Society's 2023 report, leukemia, lymphoma, and myeloma are projected to cause the deaths of approximately 57,380 people in the US in 2023. This equates to roughly 157 individuals per day or more than six deaths every hour from blood cancer. Thus, the increasing prevalence of hematological disorders is a driving force behind the graft versus host disease (GVHD) treatment market.

Key players in the GVHD treatment market are actively developing advanced drugs and seeking regulatory approval to gain a competitive edge. Product approvals play a crucial role in ensuring that healthcare products meet the necessary standards for safety, efficacy, and quality before they are made available to patients. For instance, in March 2023, Incyte Corporation, a US-based healthcare company, developed ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, which received approval from the Food and Drug Administration (FDA) for once-daily use in treating specific types of myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).

In September 2021, Sanofi, a France-based healthcare company, acquired Kadmon for $1.9 billion, strategically aiming to bolster its general medicines core assets and expand its transplant portfolio by incorporating Rezurock (belumosudil), an FDA-approved treatment for chronic graft-versus-host disease (cGVHD). Kadmon Corporation, based in the US, specializes in offering treatments for Graft Versus Host Disease (GvHD), including Rezurock (belumosudil).

Major companies operating in the graft versus host disease (GVHD) treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol Myers Squibb, AstraZeneca, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly And Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Biogen Inc., Astellas Pharma Inc., Jazz Pharmaceuticals plc, Allergan plc, Incyte Corporation, Mallinckrodt Pharmaceuticals, Genzyme Corporation, Kiadis Pharma, Neovii Pharmaceuticals AG, ElsaLys Biotech SA, Mesoblast Ltd., Soligenix.

North America was the largest region in the graft versus host disease (GVHD) treatment market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the graft versus host disease (GVHD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the graft versus host disease (GVHD) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Graft versus host disease (GVHD) treatment encompasses a range of medical interventions designed to manage or mitigate the complications stemming from GVHD, a condition wherein transplanted donor cells attack the recipient's tissues. These treatments are employed to address the ramifications of GVHD, a disease characterized by the recipient's tissues being targeted by transplanted donor cells.

The primary product types utilized in graft versus host disease (GVHD) treatment include corticosteroids, monoclonal antibodies, immunosuppressants, among others. Corticosteroids are a class of steroid hormones produced in the adrenal cortex of vertebrates, as well as synthetic analogues of these hormones. GVHD treatment addresses various disease types such as acute GVHD, prophylaxis GVHD, and chronic GVHD. These treatments are utilized by diverse end users including hospital pharmacies, retail pharmacies, and online pharmacies.

The graft versus host disease (GVHD) treatment market research report is one of a series of new reports that provides graft versus host disease (GVHD) treatment market statistics, including graft versus host disease (GVHD) treatment industry global market size, regional shares, competitors with a graft versus host disease (GVHD) treatment market share, detailed graft versus host disease (GVHD) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the graft versus host disease (GVHD) treatment industry. This graft versus host disease (GVHD) treatment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The graft versus host disease (GVHD) treatment market includes revenues earned by entities by immunosuppressive medications, clinical trials, specialized therapies and stem cell transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.